---
title: "cbdMD, Inc. (YCBD.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/YCBD.US.md"
symbol: "YCBD.US"
name: "cbdMD, Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-20T18:41:07.703Z"
locales:
  - [en](https://longbridge.com/en/quote/YCBD.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/YCBD.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/YCBD.US.md)
---

# cbdMD, Inc. (YCBD.US)

## Company Overview

cbdMD, Inc. produces and distributes various cannabidiol (CBD) products in the United States and internationally. The company owns and operates various consumer hemp-based CBD brands. Its cbdMD brand products include oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.cbdmd.com](https://www.cbdmd.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:16.000Z

**Overall: C (0.42)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 0 / 189 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | 0.00% |  |
| P/B Ratio | 0.85 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 7871670.75 |  |
| Revenue | 19984530.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -68.90% | E |
| Profit Margin | -12.25% | D |
| Gross Margin | 59.82% | A |
| Revenue YoY | -0.66% | D |
| Net Profit YoY | 44.50% | B |
| Total Assets YoY | 2.07% | C |
| Net Assets YoY | 405.61% | A |
| Cash Flow Margin | 52.41% | C |
| OCF YoY | -0.66% | D |
| Turnover | 1.64 | A |
| Gearing Ratio | 23.55% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - cbdMD, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.85",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "7871670.75",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "19984530.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-68.90%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-12.25%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "59.82%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-0.66%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "44.50%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "2.07%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "405.61%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "52.41%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-0.66%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "1.64",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "23.55%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.53 | 142/189 | - | - | - |
| PB | 0.85 | 39/189 | 3.31 | 1.14 | 0.91 |
| PS (TTM) | 0.39 | 13/189 | 0.50 | 0.41 | 0.34 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Overweight | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.73 |
| Highest Target | 2.00 |
| Lowest Target | 2.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/YCBD.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/YCBD.US/norm.md)
- [Related News](https://longbridge.com/en/quote/YCBD.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/YCBD.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**